Alatrofloxacin

	WikiDoc Resources for Alatrofloxacin
Articles
Most recent articles on Alatrofloxacin Most cited articles on Alatrofloxacin Review articles on Alatrofloxacin Articles on Alatrofloxacin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Alatrofloxacin Images of Alatrofloxacin Photos of Alatrofloxacin Podcasts & MP3s on Alatrofloxacin Videos on Alatrofloxacin
Evidence Based Medicine
Cochrane Collaboration on Alatrofloxacin Bandolier on Alatrofloxacin TRIP on Alatrofloxacin
Clinical Trials
Ongoing Trials on Alatrofloxacin at Clinical Trials.gov Trial results on Alatrofloxacin Clinical Trials on Alatrofloxacin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Alatrofloxacin NICE Guidance on Alatrofloxacin NHS PRODIGY Guidance FDA on Alatrofloxacin CDC on Alatrofloxacin
Books
Books on Alatrofloxacin
News
Alatrofloxacin in the news Be alerted to news on Alatrofloxacin News trends on Alatrofloxacin
Commentary
Blogs on Alatrofloxacin
Definitions
Definitions of Alatrofloxacin
Patient Resources / Community
Patient resources on Alatrofloxacin Discussion groups on Alatrofloxacin Patient Handouts on Alatrofloxacin Directions to Hospitals Treating Alatrofloxacin Risk calculators and risk factors for Alatrofloxacin
Healthcare Provider Resources
Symptoms of Alatrofloxacin Causes & Risk Factors for Alatrofloxacin Diagnostic studies for Alatrofloxacin Treatment of Alatrofloxacin
Continuing Medical Education (CME)
CME Programs on Alatrofloxacin
International
Alatrofloxacin en Espanol Alatrofloxacin en Francais
Business
Alatrofloxacin in the Marketplace Patents on Alatrofloxacin
Experimental / Informatics
List of terms related to Alatrofloxacin

Alatrofloxacin
	File:Alatrofloxacin.svg
Clinical data
Pregnancy; category	US: C (Risk not ruled out) ; ;
Routes of; administration	Intravenous
Legal status
Legal status	Withdrawn;
Pharmacokinetic data
Bioavailability	N/A
Protein binding	76% (trovafloxacin)
Metabolism	Quickly hydrolyzed to trovafloxacin
Elimination half-life	9 to 12 hours (trovafloxacin)
Excretion	Fecal and renal (trovafloxacin)
Identifiers
	IUPAC name 7-[(1R,5S)-6-{[(2S)-1-{[(2S)-2-aminopropanoyl]amino}-; 1-oxopropan-2-yl]amino}-3-azabicyclo[3.1.0]hexan-3-yl]-; 1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,8-naphthyridine-; 3-carboxylic acid;
CAS Number	157182-32-6 157605-25-9 (mesylate);
PubChem CID	5489474;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C26H25F3N6O5
Molar mass	558.509 g/mol

Alatrofloxacin (Trovan IV) is a fluoroquinolone antibiotic developed by Pfizer, delivered as a mesylate salt.^[1] It is the parental prodrug of trovafloxacin (Trovan) meant for intravenous administration. Trovafloxacin is a broad-spectrum antibiotic introduced in 1998 which encountered criticism for its Nigerian trials and adverse clinical reactions.^[2]^[3]

Trovafloxacin and alatrofloxacin were both withdrawn from the U.S. market in 2001.

References

↑ "PubChem CID 5489474".
↑ Hall IH, Schwab UE, Ward ES, Ives TJ (2003). "Effects of alatrofloxacin, the parental prodrug of trovafloxacin, on phagocytic, anti-inflammatory and immunomodulation events of human THP-1 monocytes". Biomed. Pharmacother. 57 (8): 359–65. PMID 14568230.
↑ Lenzer J (2006). "Secret report surfaces showing that Pfizer was at fault in Nigerian drug tests". BMJ. 332 (7552): 1233. doi:10.1136/bmj.332.7552.1233-a. PMID 16735322.

Template:WH Template:WS

[1] "PubChem CID 5489474".

[2] Hall IH, Schwab UE, Ward ES, Ives TJ (2003). "Effects of alatrofloxacin, the parental prodrug of trovafloxacin, on phagocytic, anti-inflammatory and immunomodulation events of human THP-1 monocytes". Biomed. Pharmacother. 57 (8): 359–65. PMID 14568230.

[3] Lenzer J (2006). "Secret report surfaces showing that Pfizer was at fault in Nigerian drug tests". BMJ. 332 (7552): 1233. doi:10.1136/bmj.332.7552.1233-a. PMID 16735322.

[1]

[2]

[3]

Clinical data
File:Alatrofloxacin.svg
Pregnancy category	US: C (Risk not ruled out)
Routes of administration	Intravenous
Legal status
Legal status	Withdrawn
Pharmacokinetic data
Bioavailability	N/A
Protein binding	76% (trovafloxacin)
Metabolism	Quickly hydrolyzed to trovafloxacin
Elimination half-life	9 to 12 hours (trovafloxacin)
Excretion	Fecal and renal (trovafloxacin)
Identifiers
IUPAC name 7-[(1R,5S)-6-{[(2S)-1-{[(2S)-2-aminopropanoyl]amino}- 1-oxopropan-2-yl]amino}-3-azabicyclo[3.1.0]hexan-3-yl]- 1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,8-naphthyridine- 3-carboxylic acid
CAS Number	157182-32-6 157605-25-9 (mesylate)
PubChem CID	5489474
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₂₆H₂₅F₃N₆O₅
Molar mass	558.509 g/mol

Alatrofloxacin

References

Navigation menu